Expanding the Role of NGS and Retesting in Early and Refractory NSCLC: Jonathan Thompson, MD, MS

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective retesting at progression can identify resistance mutations or new targets to optimize value-based care.